Insights

Share

FCPA_2022_Year_in_Review_SOCIAL

FCPA 2022 Year in Review

February 28, 2023 White Paper

Foreign Corrupt Practices Act ("FCPA") enforcement has yet to rebound from the immediate pre-pandemic period. In 2022, DOJ and SEC resolved eight corporate FCPA matters for $878 million, including four resolutions coordinated with foreign regulators. DOJ also announced seven indictments and pleas under the FCPA, and SEC announced no individual FCPA enforcement actions. The drop in FCPA enforcement statistics is likely temporary. The Biden administration continues to prioritize anticorruption enforcement, announcing several major changes to corporate criminal enforcement policies and corporate compliance programs, signaling a more aggressive posture toward corporate and individual FCPA enforcement.  

This White Paper reviews 2022 FCPA enforcement and describes what lies ahead.

Read the White Paper here.

Insights by Jones Day should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request permission to reprint or reuse any of our Insights, please use our “Contact Us” form, which can be found on our website at www.jonesday.com. This Insight is not intended to create, and neither publication nor receipt of it constitutes, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.
Contributors
You May Also Be Interested In

May 16, 2025 Alert

Georgia Limits Liability for Pesticide Manufacturers

May 06, 2025 Alert

OMB Directs Agencies to Accelerate AI Adoption and Devise Governance Strategy

April 25, 2025 Commentary

Georgia Enacts Major Tort Reform Legislation

April 02, 2025 Newsletters

Blurring the Line Between the Dry and Wet Lab: Joint Inventorship in AI-Assisted Life Science Inventions

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.